WallStreetZenWallStreetZen

NASDAQ: CPRX
Catalyst Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CPRX

Based on 5 analysts offering 12 month price targets for Catalyst Pharmaceuticals Inc

Min Forecast
$30.00+33.21%
Avg Forecast
$33.20+47.42%
Max Forecast
$36.00+59.86%

Should I buy or sell CPRX stock?

Based on 5 analysts offering ratings for Catalyst Pharmaceuticals Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their CPRX stock forecasts and price targets.

CPRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-03
lockedlocked$00.00+00.00%2025-02-28
lockedlocked$00.00+00.00%2025-02-27
lockedlocked$00.00+00.00%2025-01-09
lockedlocked$00.00+00.00%2024-11-11Find Out Why

1 of 1

Forecast return on equity

Is CPRX forecast to generate an efficient return?

Company
44.4%
Industry
147.71%
Market
81.76%
CPRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CPRX forecast to generate an efficient return on assets?

Company
37.94%
Industry
35.52%
CPRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CPRX earnings per share forecast

What is CPRX's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$2.09+51.45%
Avg 2 year Forecast
$2.38+72.46%
Avg 3 year Forecast
$2.37+71.74%
CPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

CPRX revenue forecast

What is CPRX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$557.2M+13.31%
Avg 2 year Forecast
$622.3M+26.54%
Avg 3 year Forecast
$759.1M+54.37%
CPRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CPRX earnings growth forecast

How is CPRX forecast to perform vs Biotechnology companies and vs the US market?

Company
21.62%
Industry
13.37%
Market
18.2%
CPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
CPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
CPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

CPRX revenue growth forecast

How is CPRX forecast to perform vs Biotechnology companies and vs the US market?

Company
14.8%
Industry
65.42%
Market
10.4%
CPRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CPRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CPRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CPRX$22.52$33.20+47.42%Strong Buy
XENE$35.11$58.00+65.20%Strong Buy
VKTX$23.94$79.25+231.04%Strong Buy
CRNX$30.42$72.20+137.34%Strong Buy
PTGX$46.28$69.33+49.81%Strong Buy
View Top Biotech Stocks

Catalyst Pharmaceuticals Stock Forecast FAQ

Is Catalyst Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: CPRX) stock is to Strong Buy CPRX stock.

Out of 5 analysts, 3 (60%) are recommending CPRX as a Strong Buy, 2 (40%) are recommending CPRX as a Buy, 0 (0%) are recommending CPRX as a Hold, 0 (0%) are recommending CPRX as a Sell, and 0 (0%) are recommending CPRX as a Strong Sell.

If you're new to stock investing, here's how to buy Catalyst Pharmaceuticals stock.

What is CPRX's earnings growth forecast for 2025-2027?

(NASDAQ: CPRX) Catalyst Pharmaceuticals's forecast annual earnings growth rate of 21.62% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.37%, and it is also forecast to beat the US market's average forecast earnings growth rate of 18.2%.

Catalyst Pharmaceuticals's earnings in 2025 is $163,889,000.On average, 3 Wall Street analysts forecast CPRX's earnings for 2025 to be $253,829,779, with the lowest CPRX earnings forecast at $245,328,303, and the highest CPRX earnings forecast at $270,832,731. On average, 3 Wall Street analysts forecast CPRX's earnings for 2026 to be $289,050,179, with the lowest CPRX earnings forecast at $273,261,724, and the highest CPRX earnings forecast at $299,980,648.

In 2027, CPRX is forecast to generate $287,835,682 in earnings, with the lowest earnings forecast at $287,835,682 and the highest earnings forecast at $287,835,682.

What is CPRX's revenue growth forecast for 2025-2027?

(NASDAQ: CPRX) Catalyst Pharmaceuticals's forecast annual revenue growth rate of 14.8% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.

Catalyst Pharmaceuticals's revenue in 2025 is $491,734,000.On average, 4 Wall Street analysts forecast CPRX's revenue for 2025 to be $67,672,355,014, with the lowest CPRX revenue forecast at $67,415,488,994, and the highest CPRX revenue forecast at $67,863,638,221. On average, 4 Wall Street analysts forecast CPRX's revenue for 2026 to be $75,572,290,723, with the lowest CPRX revenue forecast at $72,785,992,738, and the highest CPRX revenue forecast at $79,367,349,543.

In 2027, CPRX is forecast to generate $92,191,947,312 in revenue, with the lowest revenue forecast at $82,028,311,484 and the highest revenue forecast at $110,883,535,015.

What is CPRX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CPRX) forecast ROA is 37.94%, which is higher than the forecast US Biotechnology industry average of 35.52%.

What is CPRX's Price Target?

According to 5 Wall Street analysts that have issued a 1 year CPRX price target, the average CPRX price target is $33.20, with the highest CPRX stock price forecast at $36.00 and the lowest CPRX stock price forecast at $30.00.

On average, Wall Street analysts predict that Catalyst Pharmaceuticals's share price could reach $33.20 by Mar 3, 2026. The average Catalyst Pharmaceuticals stock price prediction forecasts a potential upside of 47.42% from the current CPRX share price of $22.52.

What is CPRX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CPRX) Catalyst Pharmaceuticals's current Earnings Per Share (EPS) is $1.38. On average, analysts forecast that CPRX's EPS will be $2.09 for 2025, with the lowest EPS forecast at $2.02, and the highest EPS forecast at $2.23. On average, analysts forecast that CPRX's EPS will be $2.38 for 2026, with the lowest EPS forecast at $2.25, and the highest EPS forecast at $2.47. In 2027, CPRX's EPS is forecast to hit $2.37 (min: $2.37, max: $2.37).

What is CPRX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CPRX) forecast ROE is 44.4%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.